Jeff P. Sharman, MD: Ublituximab Plus Ibrutinib Improves Response Rate in High-Risk CLL

The novel anti-CD20 monoclonal antibody ublituximab (when added to ibrutinib) yielded superior response rates than ibrutinib alone in patients with high-risk chronic lymphocytic leukemia. Dr. Sharman discusses results of the phase III GENUINE study.

SHARE